Detalhe da pesquisa
1.
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet
; 389(10088): 2492-2502, 2017 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28434648
2.
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial.
Hepatology
; 60(5): 1697-707, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24996197
3.
Corrigendum to "Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis" [J Hepatol 71 (2019) 543-552].
J Hepatol
; 71(6): 1278, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-31668671